02:47 PM EDT, 07/30/2024 (MT Newswires) -- Vertex Pharmaceuticals ( VRTX ) said Tuesday that its new drug application submission for suzetrigine has been accepted by the US Food and Drug Administration to treat moderate-to-severe acute pain.

The company said Suzetrigine has been granted priority review by the FDA, with a Prescription Drug User Fee Act target action date of Jan. 30, 2025, by which the FDA must respond.

Price: 500.98, Change: +2.83, Percent Change: +0.57